247 related articles for article (PubMed ID: 33495313)
21. Neutrophil-to-lymphocyte Ratio as a Predictive Marker of Response to Abiraterone Acetate: A Retrospective Analysis of the COU302 Study.
Loubersac T; Nguile-Makao M; Pouliot F; Fradet V; Toren P
Eur Urol Oncol; 2020 Jun; 3(3):298-305. PubMed ID: 31411963
[TBL] [Abstract][Full Text] [Related]
22. p300/CBP inhibition enhances the efficacy of programmed death-ligand 1 blockade treatment in prostate cancer.
Liu J; He D; Cheng L; Huang C; Zhang Y; Rao X; Kong Y; Li C; Zhang Z; Liu J; Jones K; Napier D; Lee EY; Wang C; Liu X
Oncogene; 2020 May; 39(19):3939-3951. PubMed ID: 32203167
[TBL] [Abstract][Full Text] [Related]
23. Cabozantinib Inhibits Abiraterone's Upregulation of IGFIR Phosphorylation and Enhances Its Anti-Prostate Cancer Activity.
Wang X; Huang Y; Christie A; Bowden M; Lee GS; Kantoff PW; Sweeney CJ
Clin Cancer Res; 2015 Dec; 21(24):5578-87. PubMed ID: 26289068
[TBL] [Abstract][Full Text] [Related]
24. Histone acetylation by p300 is involved in CREB-mediated transcription on chromatin.
Yuan LW; Gambee JE
Biochim Biophys Acta; 2001 Dec; 1541(3):161-9. PubMed ID: 11755210
[TBL] [Abstract][Full Text] [Related]
25. Transcriptional co-activator p300 maintains basal hepatic gluconeogenesis.
He L; Naik K; Meng S; Cao J; Sidhaye AR; Ma A; Radovick S; Wondisford FE
J Biol Chem; 2012 Sep; 287(38):32069-77. PubMed ID: 22815486
[TBL] [Abstract][Full Text] [Related]
26. Analysis of AR-FL and AR-V1 in Whole Blood of Patients with Castration Resistant Prostate Cancer as a Tool for Predicting Response to Abiraterone Acetate.
Stuopelyte K; Sabaliauskaite R; Bakavicius A; Haflidadóttir BS; Visakorpi T; Väänänen RM; Patel C; Danila DC; Lilja H; Lazutka JR; Ulys A; Jankevicius F; Jarmalaite S
J Urol; 2020 Jul; 204(1):71-78. PubMed ID: 32068491
[TBL] [Abstract][Full Text] [Related]
27. Role of the transcriptional coactivator CBP/p300 in linking basic helix-loop-helix and CREB responses for follicle-stimulating hormone-mediated activation of the transferrin promoter in Sertoli cells.
Chaudhary J; Skinner MK
Biol Reprod; 2001 Aug; 65(2):568-74. PubMed ID: 11466227
[TBL] [Abstract][Full Text] [Related]
28. Salt-inducible kinase 2 regulates mitotic progression and transcription in prostate cancer.
Bon H; Wadhwa K; Schreiner A; Osborne M; Carroll T; Ramos-Montoya A; Ross-Adams H; Visser M; Hoffmann R; Ahmed AA; Neal DE; Mills IG
Mol Cancer Res; 2015 Apr; 13(4):620-635. PubMed ID: 25548099
[TBL] [Abstract][Full Text] [Related]
29. Abiraterone acetate to treat metastatic castration-resistant prostate cancer in combination with prednisone.
Duarte C; Jimeno A; Kessler ER
Drugs Today (Barc); 2019 Jan; 55(1):5-15. PubMed ID: 30740608
[TBL] [Abstract][Full Text] [Related]
30. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302).
Rathkopf DE; Smith MR; de Bono JS; Logothetis CJ; Shore ND; de Souza P; Fizazi K; Mulders PF; Mainwaring P; Hainsworth JD; Beer TM; North S; Fradet Y; Van Poppel H; Carles J; Flaig TW; Efstathiou E; Yu EY; Higano CS; Taplin ME; Griffin TW; Todd MB; Yu MK; Park YC; Kheoh T; Small EJ; Scher HI; Molina A; Ryan CJ; Saad F
Eur Urol; 2014 Nov; 66(5):815-25. PubMed ID: 24647231
[TBL] [Abstract][Full Text] [Related]
31. Cooperative interactions between CBP and TORC2 confer selectivity to CREB target gene expression.
Ravnskjaer K; Kester H; Liu Y; Zhang X; Lee D; Yates JR; Montminy M
EMBO J; 2007 Jun; 26(12):2880-9. PubMed ID: 17476304
[TBL] [Abstract][Full Text] [Related]
32. TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate.
Danila DC; Anand A; Sung CC; Heller G; Leversha MA; Cao L; Lilja H; Molina A; Sawyers CL; Fleisher M; Scher HI
Eur Urol; 2011 Nov; 60(5):897-904. PubMed ID: 21802835
[TBL] [Abstract][Full Text] [Related]
33. Temporal recruitment of transcription factors at the 3',5'-cyclic adenosine 5'-monophosphate-response element of the human GnRH-II promoter.
Poon SL; An BS; So WK; Hammond GL; Leung PC
Endocrinology; 2008 Oct; 149(10):5162-71. PubMed ID: 18599546
[TBL] [Abstract][Full Text] [Related]
34. p300 acetyltransferase regulates androgen receptor degradation and PTEN-deficient prostate tumorigenesis.
Zhong J; Ding L; Bohrer LR; Pan Y; Liu P; Zhang J; Sebo TJ; Karnes RJ; Tindall DJ; van Deursen J; Huang H
Cancer Res; 2014 Mar; 74(6):1870-1880. PubMed ID: 24480624
[TBL] [Abstract][Full Text] [Related]
35. Nemo-like kinase as a negative regulator of nuclear receptor Nurr1 gene transcription in prostate cancer.
Wang J; Yang ZH; Chen H; Li HH; Chen LY; Zhu Z; Zou Y; Ding CC; Yang J; He ZW
BMC Cancer; 2016 Mar; 16():257. PubMed ID: 27036119
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics, pharmacodynamics and clinical efficacy of abiraterone acetate for treating metastatic castration-resistant prostate cancer.
Han CS; Patel R; Kim IY
Expert Opin Drug Metab Toxicol; 2015 Jun; 11(6):967-75. PubMed ID: 25936418
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of Response to Enzalutamide Consecutively After Abiraterone Acetate/Prednisone Failure in Patients With Metastatic Castration-resistant Prostate Cancer.
Emamekhoo H; Barata PC; Edwin NC; Woo KM; Grivas P; Garcia JA
Clin Genitourin Cancer; 2018 Dec; 16(6):429-436. PubMed ID: 30236961
[TBL] [Abstract][Full Text] [Related]
38. Duration of response to first androgen deprivation therapy, time to castration resistance prostate cancer, and outcome of metastatic castration resistance prostate cancer patients treated with abiraterone acetate.
Giacinti S; Carlini P; Roberto M; Bassanelli M; Strigari L; Pavese F; Aschelter AM; Felici A; Valeriani M; Cognetti F; Marchetti P
Anticancer Drugs; 2017 Jan; 28(1):110-115. PubMed ID: 27763885
[TBL] [Abstract][Full Text] [Related]
39. Therapeutic Targeting of the CBP/p300 Bromodomain Blocks the Growth of Castration-Resistant Prostate Cancer.
Jin L; Garcia J; Chan E; de la Cruz C; Segal E; Merchant M; Kharbanda S; Raisner R; Haverty PM; Modrusan Z; Ly J; Choo E; Kaufman S; Beresini MH; Romero FA; Magnuson S; Gascoigne KE
Cancer Res; 2017 Oct; 77(20):5564-5575. PubMed ID: 28819026
[TBL] [Abstract][Full Text] [Related]
40. Association of AR-V7 and Prostate-Specific Antigen RNA Levels in Blood with Efficacy of Abiraterone Acetate and Enzalutamide Treatment in Men with Prostate Cancer.
Qu F; Xie W; Nakabayashi M; Zhang H; Jeong SH; Wang X; Komura K; Sweeney CJ; Sartor O; Lee GM; Kantoff PW
Clin Cancer Res; 2017 Feb; 23(3):726-734. PubMed ID: 27489290
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
